(INSM) Insmed - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4576693075
Stock: Rare Disease Therapies, Lung Disease Treatments, Gene Therapy
Total Rating 33
Risk 26
Buy Signal -0.88
| Risk 5d forecast | |
|---|---|
| Volatility | 46.7% |
| Relative Tail Risk | -9.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.38 |
| Alpha | 73.47 |
| Character TTM | |
|---|---|
| Beta | 0.249 |
| Beta Downside | 2.475 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.72% |
| CAGR/Max DD | 2.84 |
EPS (Earnings per Share)
Revenue
Description: INSM Insmed March 04, 2026
Insmed Inc. is a biotechnology company focused on therapies for serious and rare diseases.
Their primary commercial product, ARIKAYCE, treats refractory nontuberculous mycobacterial lung infections. This product addresses a niche market within infectious diseases.
The company has several drug candidates in clinical trials, including brensocatib for bronchiectasis and treprostinil palmitil inhalation powder for pulmonary hypertension. Developing new drugs is a core activity in the biotechnology sector.
Insmed also has early-stage programs in gene therapy. Further research on ValueRay can provide detailed insights into their clinical pipeline and market potential.
Headlines to watch out for
- ARIKAYCE sales growth drives revenue
- Brensocatib clinical trial results impact future sales
- Treprostinil palmitil inhalation powder development costs
- Gene therapy pipeline success influences valuation
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -1.28b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.44 > 0.02 and ΔFCF/TA -9.20 > 1.0 |
| NWC/Revenue: 218.5% < 20% (prev 364.1%; Δ -145.5% < -1%) |
| CFO/TA -0.41 > 3% & CFO -935.0m > Net Income -1.28b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (213.6m) vs 12m ago 19.34% < -2% |
| Gross Margin: 79.41% > 18% (prev 0.76%; Δ 7864 % > 0.5%) |
| Asset Turnover: 28.27% > 50% (prev 17.96%; Δ 10.31% > 0%) |
| Interest Coverage Ratio: -14.23 > 6 (EBITDA TTM -1.18b / Interest Expense TTM 83.8m) |
Altman Z'' -11.89
| A: 0.59 (Total Current Assets 1.79b - Total Current Liabilities 468.9m) / Total Assets 2.26b |
| B: -2.49 (Retained Earnings -5.64b / Total Assets 2.26b) |
| C: -0.56 (EBIT TTM -1.19b / Avg Total Assets 2.14b) |
| D: -3.69 (Book Value of Equity -5.63b / Total Liabilities 1.53b) |
| Altman-Z'' Score: -11.89 = D |
Beneish M -2.21
| DSRI: 1.62 (Receivables 140.9m/52.0m, Revenue 606.4m/363.7m) |
| GMI: 0.96 (GM 79.41% / 76.43%) |
| AQI: 1.03 (AQ_t 0.15 / AQ_t-1 0.14) |
| SGI: 1.67 (Revenue 606.4m / 363.7m) |
| TATA: -0.15 (NI -1.28b - CFO -935.0m) / TA 2.26b) |
| Beneish M-Score: -2.21 (Cap -4..+1) = BB |
What is the price of INSM shares?
As of March 09, 2026, the stock is trading at USD 140.13 with a total of 2,486,741 shares traded.
Over the past week, the price has changed by -4.23%, over one month by -6.29%, over three months by -28.71% and over the past year by +91.78%.
Over the past week, the price has changed by -4.23%, over one month by -6.29%, over three months by -28.71% and over the past year by +91.78%.
Is INSM a buy, sell or hold?
Insmed has received a consensus analysts rating of 4.74.
Therefore, it is recommended to buy INSM.
- StrongBuy: 14
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the INSM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 212.5 | 51.7% |
| Analysts Target Price | 212.5 | 51.7% |
INSM Fundamental Data Overview March 04, 2026
P/E Forward = 16.3666
P/S = 51.4594
P/B = 33.6814
P/EG = 1.0916
Revenue TTM = 606.4m USD
EBIT TTM = -1.19b USD
EBITDA TTM = -1.18b USD
Long Term Debt = 541.0m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 768.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 257.7m USD (from netDebt column, last quarter)
Enterprise Value = 30.54b USD (31.21b + Debt 768.2m - CCE 1.43b)
Interest Coverage Ratio = -14.23 (Ebit TTM -1.19b / Interest Expense TTM 83.8m)
EV/FCF = -30.62x (Enterprise Value 30.54b / FCF TTM -997.6m)
FCF Yield = -3.27% (FCF TTM -997.6m / Enterprise Value 30.54b)
FCF Margin = -164.5% (FCF TTM -997.6m / Revenue TTM 606.4m)
Net Margin = -210.5% (Net Income TTM -1.28b / Revenue TTM 606.4m)
Gross Margin = 79.41% ((Revenue TTM 606.4m - Cost of Revenue TTM 124.9m) / Revenue TTM)
Gross Margin QoQ = 82.51% (prev 79.37%)
Tobins Q-Ratio = 13.49 (Enterprise Value 30.54b / Total Assets 2.26b)
Interest Expense / Debt = 2.68% (Interest Expense 20.6m / Debt 768.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -942.3m (EBIT -1.19b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.83 (Total Current Assets 1.79b / Total Current Liabilities 468.9m)
Debt / Equity = 1.04 (Debt 768.2m / totalStockholderEquity, last quarter 739.0m)
Debt / EBITDA = -0.22 (negative EBITDA) (Net Debt 257.7m / EBITDA -1.18b)
Debt / FCF = -0.26 (negative FCF - burning cash) (Net Debt 257.7m / FCF TTM -997.6m)
Total Stockholder Equity = 758.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.53% (Net Income -1.28b / Total Assets 2.26b)
RoE = -168.4% (Net Income TTM -1.28b / Total Stockholder Equity 758.4m)
RoCE = -91.80% (EBIT -1.19b / Capital Employed (Equity 758.4m + L.T.Debt 541.0m))
RoIC = -65.46% (negative operating profit) (NOPAT -942.3m / Invested Capital 1.44b)
WACC = 6.72% (E(31.21b)/V(31.97b) * Re(6.83%) + D(768.2m)/V(31.97b) * Rd(2.68%) * (1-Tc(0.21)))
Discount Rate = 6.83% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 21.46%
[DCF] Fair Price = unknown (Cash Flow -997.6m)
EPS Correlation: -70.47 | EPS CAGR: -20.85% | SUE: -1.41 | # QB: 0
Revenue Correlation: 89.05 | Revenue CAGR: 53.34% | SUE: 0.10 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.83 | Chg7d=-0.152 | Chg30d=-0.128 | Revisions Net=+0 | Analysts=13
EPS current Year (2026-12-31): EPS=-2.86 | Chg7d=-0.281 | Chg30d=-0.131 | Revisions Net=-2 | Growth EPS=+55.5% | Growth Revenue=+171.9%
EPS next Year (2027-12-31): EPS=0.37 | Chg7d=+0.006 | Chg30d=+0.201 | Revisions Net=+1 | Growth EPS=+113.0% | Growth Revenue=+61.5%
[Analyst] Revisions Ratio: +0.00 (3 Up / 3 Down within 30d for Next Quarter)
P/S = 51.4594
P/B = 33.6814
P/EG = 1.0916
Revenue TTM = 606.4m USD
EBIT TTM = -1.19b USD
EBITDA TTM = -1.18b USD
Long Term Debt = 541.0m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 768.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 257.7m USD (from netDebt column, last quarter)
Enterprise Value = 30.54b USD (31.21b + Debt 768.2m - CCE 1.43b)
Interest Coverage Ratio = -14.23 (Ebit TTM -1.19b / Interest Expense TTM 83.8m)
EV/FCF = -30.62x (Enterprise Value 30.54b / FCF TTM -997.6m)
FCF Yield = -3.27% (FCF TTM -997.6m / Enterprise Value 30.54b)
FCF Margin = -164.5% (FCF TTM -997.6m / Revenue TTM 606.4m)
Net Margin = -210.5% (Net Income TTM -1.28b / Revenue TTM 606.4m)
Gross Margin = 79.41% ((Revenue TTM 606.4m - Cost of Revenue TTM 124.9m) / Revenue TTM)
Gross Margin QoQ = 82.51% (prev 79.37%)
Tobins Q-Ratio = 13.49 (Enterprise Value 30.54b / Total Assets 2.26b)
Interest Expense / Debt = 2.68% (Interest Expense 20.6m / Debt 768.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -942.3m (EBIT -1.19b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.83 (Total Current Assets 1.79b / Total Current Liabilities 468.9m)
Debt / Equity = 1.04 (Debt 768.2m / totalStockholderEquity, last quarter 739.0m)
Debt / EBITDA = -0.22 (negative EBITDA) (Net Debt 257.7m / EBITDA -1.18b)
Debt / FCF = -0.26 (negative FCF - burning cash) (Net Debt 257.7m / FCF TTM -997.6m)
Total Stockholder Equity = 758.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.53% (Net Income -1.28b / Total Assets 2.26b)
RoE = -168.4% (Net Income TTM -1.28b / Total Stockholder Equity 758.4m)
RoCE = -91.80% (EBIT -1.19b / Capital Employed (Equity 758.4m + L.T.Debt 541.0m))
RoIC = -65.46% (negative operating profit) (NOPAT -942.3m / Invested Capital 1.44b)
WACC = 6.72% (E(31.21b)/V(31.97b) * Re(6.83%) + D(768.2m)/V(31.97b) * Rd(2.68%) * (1-Tc(0.21)))
Discount Rate = 6.83% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 21.46%
[DCF] Fair Price = unknown (Cash Flow -997.6m)
EPS Correlation: -70.47 | EPS CAGR: -20.85% | SUE: -1.41 | # QB: 0
Revenue Correlation: 89.05 | Revenue CAGR: 53.34% | SUE: 0.10 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.83 | Chg7d=-0.152 | Chg30d=-0.128 | Revisions Net=+0 | Analysts=13
EPS current Year (2026-12-31): EPS=-2.86 | Chg7d=-0.281 | Chg30d=-0.131 | Revisions Net=-2 | Growth EPS=+55.5% | Growth Revenue=+171.9%
EPS next Year (2027-12-31): EPS=0.37 | Chg7d=+0.006 | Chg30d=+0.201 | Revisions Net=+1 | Growth EPS=+113.0% | Growth Revenue=+61.5%
[Analyst] Revisions Ratio: +0.00 (3 Up / 3 Down within 30d for Next Quarter)